Biotech Startups

Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.

4 investors

Videra provides AI-powered technology that supports behavioral health clinicians by enhancing their capabilities and patient engagement to improve care delivery and outcomes. The platform serves behavioral health providers and healthcare systems, focusing on democratizing access to quality mental health care.

4 investors

Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature. The company develops therapeutics for disease by generating entirely new molecules with the targeting precision of antibodies but in pill form.

4 investors

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases. It is run by a team of physicians, scientists, and drug-development specialists focused on neurological conditions.

4 investors

Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities. The company targets patients with unmet medical needs across these therapeutic areas.

4 investors

Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms. The company initially focuses on non-alcoholic steatohepatitis (NASH) drug discovery.

4 investors

A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.

4 investors

VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs. It backs early-stage research projects and companies working on drug discovery and interventions to extend human healthspan and lifespan.

4 investors

BetteRx (formerly Vitae Industries) builds the AutoCompounder, an automated dosage-making system with a vetted compound formulary that helps 503A compounding pharmacists produce personalized medications more consistently and in line with FDA regulations. It serves compounding pharmacies in the US, with installations across the country.

4 investors

Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types. The company focuses on expanding the scope and efficacy of CAR T-cell treatment for patients with limited therapeutic options.

4 investors

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.

4 investors

Vytala is a foodtech company that develops nutrition solutions to address fat malabsorption and other nutrient deficiencies. The company focuses on clinical nutrition with an emphasis on improving health outcomes through innovative food science.

4 investors

Vytelle offers an integrated technology platform for cattle producers to accelerate genetic progress and enable individual animal management. Its tools support breeding and performance decisions aimed at producing more meat and milk with fewer inputs.

4 investors

Wayfinder develops RNA-targeting small molecule therapies using expertise in RNA biophysics, molecular biology, and machine learning to discover treatments for currently incurable diseases.

4 investors

Wheeler Bio operates as a contract development and manufacturing organization (CDMO) for biomanufacturing, providing development and manufacturing expertise for biologics therapeutics.

4 investors

Windgap Medical develops and commercializes drug-device combination products, including a dual-chamber autoinjector technology for administering complex injectable medications. Serving the pharmaceutical and healthcare market, the company focuses on simplifying and automating drug delivery with an emphasis on sustainability.

4 investors

WonderTx is an AI-native biotech that develops extrapolative AI models to discover oral drug molecules for targets with validated human biology that currently lack a viable pill-based treatment. The company aims to convert injectable therapies into pills and works on both its own and partner drug discovery programs.

4 investors

Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.

4 investors

WuXi AppTec is a global Contract Research, Development and Manufacturing Organization (CRDMO) that provides integrated drug development services spanning chemistry, biology discovery, preclinical testing, and clinical research across Asia, Europe, and North America. The company serves pharmaceutical innovators seeking to accelerate the development and manufacturing of new therapies in a cost-effective manner.

4 investors

4 investors

Yuri develops in-house space labs and ground simulators that use microgravity for life sciences research, supporting drug development and cell-based therapies. It serves biotech and pharmaceutical customers, offering experiment platforms flown on the ISS and other space environments.

4 investors

Zephyr AI is a healthcare technology company. The provided page content is a biography of Grant Verstandig and Red Cell Partners rather than a description of Zephyr AI itself, so it offers no usable detail about Zephyr AI's own products or market.

4 investors

Portrai analyzes spatial transcriptomics data together with tissue staining images using AI to generate insights for drug development, supporting drug licensing asset evaluation and drug repurposing. The company applies spatial biology data to innovate the pharmaceutical R&D process.

4 investors

AmicaTerra manufactures bioplastic products from edible and non-edible plant materials, achieving cost-competitive performance through processing at Taiwan facilities. The company aims to supply these sustainable biomass-based materials globally, with plans to establish production in Japan using agricultural waste and bamboo resources.

4 investors